- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02160951
Dose Escalation Study of LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies
A Multi-center, Open-label, Dose Escalation, Phase 1 Study of Oral LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies
This is a multi-center, open-label, dose escalation, Phase 1 study of oral LGH447 in Japanese patients with relapsed and/or refractory multiple myeloma for which no standard effective treatment options exist.
The study consists of a dose escalation part to estimate the maximum tolerated dose and/or the recommended dose for expansion and a dose expansion part to further assess safety and preliminary anti-cancer activity of LGH447 at the maximum tolerated dose and/or the recommended dose for expansion.
Descripción general del estudio
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Aichi
-
Nagoya-city, Aichi, Japón, 467-8602
- Novartis Investigative Site
-
-
Hyogo
-
Kobe-city, Hyogo, Japón, 650-0017
- Novartis Investigative Site
-
-
Kyoto
-
Kyoto-city, Kyoto, Japón, 602-8566
- Novartis Investigative Site
-
-
Okayama
-
Okayama-city, Okayama, Japón, 701-1192
- Novartis Investigative Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-Confirmed diagnosis of relapsed and/or refractory MM for which no standard effective treatment options exist.
Exclusion Criteria:
-Uncontrolled cardiovascular condition, including ongoing cardiac arrhythmias, congestive heart failure, angina, or myocardial infarction within the past 6 months.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: LGH447
LGH447, QD
|
LGH447, QD
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Incidence rate of dose limiting toxicities
Periodo de tiempo: 28 days
|
Estimate the maximum tolerated dose and/or recommended dose for expansion of LGH447 in Japanese patients
|
28 days
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Number of patients with adverse events as a measure of safety and tolerability of LGH447
Periodo de tiempo: 28 days and till the end of the study, an average of 84 days
|
Adverse events, serious adverse events, changes in laboratory values, and electrocardiograms
|
28 days and till the end of the study, an average of 84 days
|
Pharmacokinetics profile of LGH447 and its metabolites if appropriate
Periodo de tiempo: Baseline, 0.5, 1, 2, 3, 4, 5, 6, 8, 24 hours on Cycle1Day1, 14 and 28 and baseline on Cycle2Day14 and Cycle3Day1
|
PK parameters such as AUC, Cmax, Tmax, T1/2.
Cycle = 28 days
|
Baseline, 0.5, 1, 2, 3, 4, 5, 6, 8, 24 hours on Cycle1Day1, 14 and 28 and baseline on Cycle2Day14 and Cycle3Day1
|
Overall Response Rate
Periodo de tiempo: Every 28 days till the end of the study, an average of 84 days
|
Describe any preliminary anti-cancer activity associated with LGH447 based on International Myeloma Working group Criteria with modification.
|
Every 28 days till the end of the study, an average of 84 days
|
Disease control rate
Periodo de tiempo: Every 28 days till the end of the study, an average of 84 days
|
Describe any preliminary anti-cancer activity associated with LGH447 based on International Myeloma Working group Criteria with modification.
|
Every 28 days till the end of the study, an average of 84 days
|
Clinical benefit rate
Periodo de tiempo: Every 28 days till the end of the study, an average of 84 days
|
Describe any preliminary anti-cancer activity associated with LGH447 based on International Myeloma Working group Criteria with modification.
|
Every 28 days till the end of the study, an average of 84 days
|
Duration of Response
Periodo de tiempo: Every 28 days till the end of the study, an average of 84 days, from the first documented onset of confirmed PR or better response to the date of documented disease progression/relapse or death due to multiple myeloma
|
Describe any preliminary anti-cancer activity associated with LGH447 based on International Myeloma Working group Criteria with modification.
|
Every 28 days till the end of the study, an average of 84 days, from the first documented onset of confirmed PR or better response to the date of documented disease progression/relapse or death due to multiple myeloma
|
Progression Free Survival
Periodo de tiempo: Every 28 days till the end of the study, an average of 84 days, from start of treatment to the date of event defined as the first documented disease progression/relapse, or death due to any cause
|
Describe any preliminary anti-cancer activity associated with LGH447 based on International Myeloma Working group Criteria with modification.
|
Every 28 days till the end of the study, an average of 84 days, from start of treatment to the date of event defined as the first documented disease progression/relapse, or death due to any cause
|
Time to response
Periodo de tiempo: Every 28 days till the end of the study, an average of 84 days, from start of treatment until first documented best overall response
|
Describe any preliminary anti-cancer activity associated with LGH447 based on International Myeloma Working group Criteria with modification.
|
Every 28 days till the end of the study, an average of 84 days, from start of treatment until first documented best overall response
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades cardiovasculares
- Enfermedades Vasculares
- Enfermedades del sistema inmunológico
- Neoplasias por tipo histológico
- Neoplasias
- Trastornos linfoproliferativos
- Trastornos inmunoproliferativos
- Neoplasias por sitio
- Enfermedades hematológicas
- Trastornos hemorrágicos
- Trastornos hemostáticos
- Paraproteinemias
- Trastornos de proteínas en sangre
- Neoplasias De Células Plasmáticas
- Neoplasias Hematológicas
- Mieloma múltiple
Otros números de identificación del estudio
- CLGH447X1101
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre LGH447
-
Novartis PharmaceuticalsTerminadoMieloma múltiple en recaída y refractarioItalia, Alemania, Singapur, Australia, Estados Unidos
-
Novartis PharmaceuticalsTerminadoAML y SMD de alto riesgoAlemania, Italia, Francia, Países Bajos, Estados Unidos, Australia, Japón
-
Novartis PharmaceuticalsTerminadoMieloma múltipleEstados Unidos, Alemania, España, Singapur